Confidential pharmaceutical agreements between the Trump administration and major drug manufacturers including Pfizer and Eli Lilly have surfaced, revealing previously hidden negotiation terms. These contracts encompass tariff exemptions, international pricing mechanisms, and extensive non-disclosure provisions that shield deal specifics from public scrutiny. The disclosure raises questions about government transparency in healthcare policy negotiations and the balance between protecting proprietary business interests and maintaining public accountability in drug pricing decisions.

Summary auto-generated by AI from the original publisher's content. Editorial standards.